Clarity for Every Lymphoma Case

Comprehensive fusion and rearrangement detection

Resolve ambiguity to deliver a precise diagnosis and optimal treatment

Aventa Lymphoma helps resolve ambiguous lymphoma diagnoses by evaluating all clinically relevant rearrangements in B- and T-cell lymphomas though a novel and proprietary genome-wide NGS-based assay

Clinical presentation, histology and immunophenotyping results don’t always point to a single lymphoma diagnosis.Therefore, the standard of care has evolved to include rearrangement analysis by FISH to diagnose important subtypes like double hit lymphoma, Burkitt lymphoma and other ambiguous cases. 

However, traditional FISH testing has many limitations — often missing rearrangements that could connect disparate findings into a definitive diagnosis, leaving cases incomplete.

Aventa Lymphoma is robust to cryptic breakpoints and detects rearrangements regardless of partner. Genome-wide, diagnosis-agnostic detection of all rearrangements ensures even the rarest are found. 

~30%

FISH testing misses ~30% of diagnosis-, prognosis- and treatment-informing fusions and rearrangements

Find them with Aventa Lymphoma

 

Common scenarios where Aventa Lymphoma can provide critical clarity include:  

  • Resolving fusion partners, especially MYC 

  • DLBCL vs. DHL/THL 

  • Burkitt vs. Burkitt-like lymphoma  

  • T-cell lymphomas

  • DLBCL vs. Mantle cell lymphoma 

  • High-grade B-cell lymphoma NOS 

  • Transformed lymphomas 

Ordering Aventa Lymphoma is easy

We handle specimen retrieval and return, and results are returned in about 10 business days.

We are committed to making our tests accessible and affordable

Aventa Assist offers programs to help patients whose costs for Aventa Lymphoma is not fully covered by insurance.